Myriad Genetics Inc.
Salt Lake City, UT
- UEI
- DGD1LL6KYLC8
- CAGE
- 1G6S8
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- KJ1FJFKF1PM9
- Salt Lake City, UT H7C7T3D6ZSB8
- Assurex Health, Inc. · Mason, OH NABWBD5Q6CU9
- KJ9RNTDFC3D1
-
- SAM.gov registration date
- Physical address
- 322 N 2200 W, Salt Lake City, UT 84116, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | -$67,473 |
| FY2024 | $209,925 |
| FY2023 | $87,465 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Myriad Genetic Laboratories Inc. | Salt Lake City, UT | 621511 Medical Laboratories |
| Labcorp Genetics Inc. | Burlington, NC | 621511 Medical Laboratories |
| Integrated Genetics And Integrated Oncology Business Units | Westborough, MA | 621511 Medical Laboratories |
| Fulgent Genetics, Inc. | El Monte, CA | 621511 Medical Laboratories |
| Invitae Corporation | — | 621511 Medical Laboratories |
About the company
Myriad Genetics Inc. is a molecular diagnostic company headquartered in Salt Lake City, Utah, specializing in genetic testing services for cancer risk assessment, treatment guidance, and disease management. Registered in the System for Award Management (SAM) since August 2, 2000, the company is a for-profit corporate entity with an active federal contract vehicle. As a parent organization with subsidiaries like Myriad Genetic Laboratories Inc., the company focuses on advanced genetic testing technologies that provide clinically actionable insights for healthcare providers and patients.
The federal contract awards demonstrate Myriad Genetics Inc.'s primary focus on providing specialized genetic testing services, predominantly to the Department of Veterans Affairs (VA) across multiple Veterans Integrated Service Networks (VISN). The majority of their contracts involve ProLaris testing, a molecular diagnostic service for prostate cancer that measures gene expression to assess cancer aggressiveness and guide treatment strategies. Contract values have ranged from $3,900 to $589,712, with performance periods typically spanning one to two years. The company has consistently been awarded firm-fixed-price contracts and purchase orders, primarily through the VA healthcare system, with additional minimal engagement with the Defense Health Agency. No set-aside designations were used in these contract awards, indicating open competition. The testing services cover various medical domains, including prostate cancer diagnostics, rheumatoid arthritis disease activity testing, and broader genetic testing capabilities, demonstrating the company's versatility in providing molecular diagnostic solutions to federal healthcare providers.
Quick answers
Is Myriad Genetics Inc. registered in SAM.gov?
Yes. Myriad Genetics Inc.'s SAM.gov registration is active through March 27, 2027.
How much has Myriad Genetics Inc. received in federal contracts?
Federal contracts obligated $229,917 to Myriad Genetics Inc. in fiscal years 2023 through 2027.
What is Myriad Genetics Inc.'s most recent federal award?
Myriad Genetics Inc.'s most recent federal contract award is Prolaris testing (36C26225C0008), from Veterans Integrated Service Network 22 (VHA), on October 1, 2024.
On GovTribe
See Myriad Genetics Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors